Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Small Cell Lung Carcinoma 27Lymphoma, Large B-Cell, Diffuse 10Lung Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Non-Hodgkin 6Lymphoma, B-Cell 6Hodgkin Disease 6Burkitt Lymphoma 6Neuroblastoma 5Medulloblastoma 5Neoplasms, Germ Cell and Embryonal 4Leukemia, Myeloid, Acute 4Small Cell Lung Cancer Extensive Stage 3Seminoma 3Retinoblastoma 3Recurrence 3Ovarian Neoplasms 3Multiple Myeloma 3Lymphoma 3Carcinoma, Neuroendocrine 3Brain Neoplasms 3Wilms Tumor 2Urinary Bladder Neoplasms 2Teratoma 2Sarcoma, Ewing 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Neuroectodermal Tumors, Primitive 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2

Interventions

X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced NUT Carcinoma × Etoposide × Clear all
NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡